bioAffinity Technologies Q2 revenue rises on CyPath Lung demand
bioAffinity Technologies Q2 revenue rises on CyPath Lung demand
Overview
US biotechnology firm's Q2 revenue rose 19% yr/yr, driven by CyPath Lung test sales
CyPath Lung test volume surged 216% yr/yr, reflecting increased physician adoption
Company completed $3.2 mln public offering to fund commercialization and clinical development
Outlook
Company prioritizes expanding physician adoption and utilization in second half of 2026
bioAffinity plans to advance pipeline for asthma, COPD diagnostics and skin cancer therapeutics
Result Drivers
PHYSICIAN ADOPTION - Co said accelerating physician adoption and integration of CyPath Lung into clinical workflows drove test volume growth
EXISTING CLIENTS - Existing clients increased CyPath Lung orders by 71% yr/yr during the first six months of 2026
EDUCATION INITIATIVES - Co expanded physician education efforts, including scientific presentations and webinars, to support adoption
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| $1.5 mln |
|
Q2 Net Loss |
| $3.4 mln |
|
Reuters Recommended Reads
Aug 5 - Biodesix Q2 revenue rises 34%, beats analyst estimates
Aug 5 - Caris Life Sciences Q2 revenue rises 45% on the back of molecular profiling services
Aug 6 - US FDA approves Replimune's skin cancer drug after prior rejections
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)